nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2016 | short review

Acute myeloid leukemia: highlights from ASH 2015

verfasst von: Prof. Michael Pfeilstöcker, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Summary

Despite of the progress achieved in recent years for acute myeloid leukemia (AML) treatment, there is still a need for improvement, both for younger and elderly patients. This review covers studies for AML presented at the ASH 2015 annual meeting. The presentations selected offer a glimpse of the future of AML treatment. Also in AML insights into the molecular pathogenesis can be translated into clinical practice where a major step has been set with the first positive trial with respect to overall survival for the tyrosine kinase inhibitor midostaurin. Also for older patients, unfit for chemotherapy, therapy options are increasingly available. Individualized therapies will require both new trial designs and new approaches for patient assessment and clinical decision making.

Vorheriger Artikel Novel strategies in the management of chronic lymphocytic leukemia (CLL)

Nächster Artikel Indolent lymphoma at ASH 2015: new treatment approaches

Papaemmanuil E, Gerstung M, Bullinger L, et al. Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML. Blood. 2015;126:803.

Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P‑controlled bouble-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6.CrossRef

Schlenk R, Döhner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose Cytarabine (NCT01477606). Blood. 2015;126:322.

Uy GL, Mandrekar S, Laumann K, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001). Blood. 2015;126:319.CrossRef

Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;126:323.

Foran JM, Sun Z, Claxton DF, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and Decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN cancer research group (E2906). Blood. 2015;126:217.

Thomas X, De Botton S, Chevret S, et al. Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/Clara study (NCT 00932412). Blood. 2015;126:218.

Russell NH, Hills RK, Freeman S, et al. A comparison of 1 or 2 courses of high dose cytarabine as consolidation in younger patients with AML: first results of the UK NCRI AML17 trial. Blood. 2015;126:221.

Röllig C, Kramer M, Gabrecht M, et al. Randomized comparison of intermediate-dose cytarabine plus mitoxantrone (IMA) versus standard-dose cytarabine plus daunorubicin (DA) for induction therapy in AML patients 〉60 years. results from the SAL 60+ trial. Blood. 2015;126:222.CrossRef

10.

Ades L, Thomas X, Guerci-Bresler A, et al. Is arsenic trioxide (ATO) required in the treatment of standard risk newly diagnosed APL? Analysis of a randomized trial (APL 2006) by the french belgian swiss APL group. Blood. 2015;126:451.

11.

Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia with 〉30 % bone marrow blasts and 〈15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data. Blood. 2015;126:2515.

12.

Seymour JF, Silverman LR, Döhner H, et al. The safety and tolerability of azacitidine (AZA) are comparable in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Blood. 2015;126:3754.

13.

DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327.CrossRef

14.

Garcia-Manero G, Berdeja JD, Komrokji RS, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911.

15.

Fathi AT, Erba HP, Lancet JE, et al. SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood. 2015;126:454.CrossRef

16.

Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2015;126:461.

17.

Kantarjian HM, Roboz GJ, Kropf PL, et al. Comparison of efficacy and safety results in 103 treatment-naïve acute myeloid leukemia (TN-AML) patients not candidates for intensive chemotherapy using 5‑day and 10-day regimens of guadecitabine (SGI-110), a novel hypomethylating agent (HMA). Blood. 2015;126:458.

18.

Voso MT, Leone G, Piciocchi A, et al. Feasibililty of azacitidine as bridge to allogeneic stem cell transplantation in patients with higher-risk MDS or low-blast count AML: results of the BMT-AZA multicenter prospective study. Blood. 2015;126:66.

19.

Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood. 2015;126:LBA-8.

20.

Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients for whom allogeneic stem cell transplantation represents the only curative therapy. Blood. 2015;126:559.CrossRef

21.

Lee SC, Dvinge H, Kim E, et al. Therapeutic targeting of spliceosomal mutant myeloid leukemias through modulation of splicing catalysis. Blood. 2015;126:4.CrossRef

Titel: Acute myeloid leukemia: highlights from ASH 2015
verfasst von: Prof. Michael Pfeilstöcker, MD, MBA
Publikationsdatum: 01.09.2016
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-016-0275-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Antiangiogenic therapies in ovarian cancer

A welcome statement from the associate Editor-in-Chief

Practice changing information in aggressive lymphoma, ASH 2015

Novel strategies in the management of chronic lymphocytic leukemia (CLL)

Welcome to the new associate Editor-in-Chief of memo

ASH 2015—insights and outlooks